Recent Advances in Personalised Gastrointestinal Cancer Treatments

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 477

Special Issue Editors

E-Mail Website
Guest Editor
Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Dr, Headington, Oxford OX3 7BN, UK
Interests: genetics; cell biology; cancer; colorectal cancer; spatial biology; drug delivery; gene therapy; cell therapy

E-Mail Website
Guest Editor
School of Pharmacy, Queen’s University Belfast, Belfast, UK
Interests: cell biology; cancer; drug delivery; gene therapy; cell therapy; peptides; prevention

Special Issue Information

Dear Colleagues,

Recent advances in our ability to understand and manipulate cancer have led to a plethora of new avenues for personalised medicine in gastrointestinal cancer treatment. 

Such advances include the use of sophisticated 3D ex vivo models of tumour epithelium (organoids), their co-culture with immune and stromal cells, the development of complex genetically engineered mouse models of cancer, and the ability to unpack cell–cell interactions on slide using multiplex imaging platforms. Together, these models can be used to explore the efficacy of novel drug delivery systems, impact of chemotherapies, radiotherapy, gene therapy, and cell therapies, to name a few. For example, patient tumour-derived organoids can be used to screen multiple drugs ex vivo in order to unpack drug efficiency/resistance on a personalised level, or multiplex image analysis could be used to understand how the delivery of particular drugs is impacting the cellular ecology of the cancers. These advances in techniques and knowledge have the capabilities to inform clinical decision making and thus improve patient prognosis.  

This Special Issue aims to collect advanced studies of personalised medicine potential in the treatment of gastrointestinal cancers. We welcome the submission of original research papers as well as review articles, with the aim of building a unique bank of knowledge which will be extremely useful to those working in the field. If you have any questions, please do not hesitate to contact me for more information.

Dr. Eoghan Joseph Mulholland
Dr. Emma McErlean
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • gastrointestinal cancer 
  • genetics 
  • cell biology 
  • drug delivery 
  • personalised medicine

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop